Drug monographs

Olaratumab and rucaparib

Dominic A. Solimando, James Waddell

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

Original languageEnglish (US)
Pages (from-to)258-263
Number of pages6
JournalHospital Pharmacy
Volume52
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Pharmacists
Oncology
Postal Service
Pharmaceutical Preparations
Product Labeling
Off-Label Use
Pharmaceutical Services
Chemotherapy
Poisons
Highway systems
Antineoplastic Agents
Labeling
Labels
Drug Therapy
rucaparib
olaratumab
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Drug monographs : Olaratumab and rucaparib. / Solimando, Dominic A.; Waddell, James.

In: Hospital Pharmacy, Vol. 52, No. 4, 01.04.2017, p. 258-263.

Research output: Contribution to journalReview article

Solimando, Dominic A. ; Waddell, James. / Drug monographs : Olaratumab and rucaparib. In: Hospital Pharmacy. 2017 ; Vol. 52, No. 4. pp. 258-263.
@article{270e80e578da40c98b75f4b06748ae3e,
title = "Drug monographs: Olaratumab and rucaparib",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.",
author = "Solimando, {Dominic A.} and James Waddell",
year = "2017",
month = "4",
day = "1",
doi = "10.1310/hpj5203-258",
language = "English (US)",
volume = "52",
pages = "258--263",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "4",

}

TY - JOUR

T1 - Drug monographs

T2 - Olaratumab and rucaparib

AU - Solimando, Dominic A.

AU - Waddell, James

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

UR - http://www.scopus.com/inward/record.url?scp=85031101358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031101358&partnerID=8YFLogxK

U2 - 10.1310/hpj5203-258

DO - 10.1310/hpj5203-258

M3 - Review article

VL - 52

SP - 258

EP - 263

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 4

ER -